Nisa Investment Advisors LLC Has $58.33 Million Holdings in Eli Lilly And Co (LLY)

Nisa Investment Advisors LLC reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 4.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 449,553 shares of the company’s stock after selling 19,443 shares during the period. Nisa Investment Advisors LLC’s holdings in Eli Lilly And Co were worth $58,334,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Vanguard Group Inc boosted its position in shares of Eli Lilly And Co by 0.7% in the third quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock worth $7,955,211,000 after acquiring an additional 511,752 shares during the last quarter. BlackRock Inc. boosted its position in shares of Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after acquiring an additional 2,030,845 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of Eli Lilly And Co by 17,720.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock worth $367,000 after acquiring an additional 42,182,367 shares during the last quarter. FMR LLC boosted its position in shares of Eli Lilly And Co by 83.9% in the fourth quarter. FMR LLC now owns 13,687,081 shares of the company’s stock worth $1,583,870,000 after acquiring an additional 6,242,865 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Eli Lilly And Co by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock worth $1,514,582,000 after acquiring an additional 830,689 shares during the last quarter. 79.58% of the stock is currently owned by institutional investors.

Several equities research analysts recently issued reports on LLY shares. UBS Group decreased their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. Argus reissued a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Barclays reissued a “buy” rating and issued a $130.00 target price on shares of Eli Lilly And Co in a research report on Sunday, January 20th. Finally, Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price on the stock in a research report on Wednesday, April 10th. Ten analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $118.02.



In related news, SVP Alfonso G. Zulueta sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Melissa S. Barnes sold 4,735 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $125.15, for a total transaction of $592,585.25. Following the completion of the transaction, the insider now owns 22,085 shares in the company, valued at approximately $2,763,937.75. The disclosure for this sale can be found here. Insiders sold 867,382 shares of company stock worth $109,265,182 in the last 90 days. 0.11% of the stock is currently owned by insiders.

NYSE LLY opened at $115.20 on Friday. Eli Lilly And Co has a one year low of $77.09 and a one year high of $132.13. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. The company has a market capitalization of $119.33 billion, a P/E ratio of 20.76, a price-to-earnings-growth ratio of 2.18 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same quarter in the previous year, the business posted $1.14 EPS. The company’s quarterly revenue was up 4.5% on a year-over-year basis. Equities research analysts predict that Eli Lilly And Co will post 5.66 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Nisa Investment Advisors LLC Has $58.33 Million Holdings in Eli Lilly And Co (LLY)” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/04/21/nisa-investment-advisors-llc-has-58-33-million-holdings-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Federal Reserve

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.